Trial Profile
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2023
Price :
$35
*
At a glance
- Drugs Masupirdine (Primary) ; Donepezil; Donepezil/memantine; Memantine
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Suven Life Sciences
- 01 Oct 2022 Results of post-hoc analysis assessing effects of masupirdine on the neuropsychiatric symptoms, published in the International Journal of Geriatric Psychiatry.
- 04 Aug 2022 Results of post-hoc analysis assessing effect of masupirdine in patients with probable alzheimer's disease, presented at the Alzheimer's Association International Conference 2022.
- 04 Aug 2022 Results of post hoc analysis assessing the impact of memantine on the efficacy of masupirdine by subdividing patients based on the use of memantine dosage form and memantine plasma concentrations, presented at the Alzheimer's Association International Conference 2022